Skip to main content

Table 2 Baseline characteristics of the study population, overall, and stratified by APOE ε4 genotype

From: CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

Characteristics

 

APOE genotype

AD patients

0 ε4

1 ε4

2 ε4

 

(N = 321)

(N = 125)

(N = 141)

(N = 55)

P value

Age, year, mean (SD)

71.0 (8.5)

71.4 (9.9)

71.4 (7.6)

69.0 (6.9)

0.07

Women, n (%)

200 (62.3)

76 (60.8)

87 (61.7)

37 (67.3)

0.70

MMSE, mean (SD)

20.3 (5.8)

20.4 (5.6)

19.8 (5.9)

21.4 (5.8)

0.16

Level of education, n (%)

 Low

106 (35.7)

48 (40.3)

44 (33.9)

14 (29.2)

 

 Intermediate

110 (37.0)

38 (31.9)

50 (38.5)

22 (45.8)

 

 High

81 (27.3)

33 (27.7)

36 (27.7)

12 (25)

0.49

APOE ε4 carriers, n (%)

196 (61.1)

Years of follow-up, mean (SD)

3.9 (2.4)

3.8 (2.5)

3.8 (2.4)

4.1 (2.6)

0.74

Death, n (%)

57 (17.8)

25 (20.0)

24 (17.0)

8 (14.6)

0.65

Institution, n (%)

71 (22.1)

26 (20.8)

35 (24.8)

10 (18.2)

0.54

CSF biomarkers, pg/mL, mean (SD)

 Aβ42

483.8 (134.8)

481.9 (136.1)

512.1 (126.1)

415.9 (130.8)

< 0.001

 Aβ40b

13,298 (5454)

12,820 (5648)

13,843 (5498)

12,928 (4897)

0.19

 Ratio Aβ42/40b

0.047 (0.022)

0.049 (0.022)

0.047 (0.024)

0.040 (0.014)

0.08

 Tau

684.9 (276.9)

677.4 (271.4)

705.2 (291.9)

649.5 (248.1)

0.61

 p-Tau 181

102.6 (39.0)

103.6 (46.4)

103.8 (35.0)

97.4 (29.6)

0.60

  1. aLow: primary school or less, intermediate: secondary to high school, high: baccalaureate or university degree
  2. bCSF Aβ40 was available for 214 patients